Skip to content
19-20 Nov 2021

Topic: General hepatology

Organised by: EASL

Location: Barcelona, Spain

Meeting Type: EASL Schools & Masterclasses

Portal Hypertension school: course directors

  • Prof. Juan Carlos Garcia-Pagan, Spain
  • Dr Virginia Hernández-Gea, Spain

Programme Overview / Summary

  1. Epidemiology and etiology of portal hypertension: Is there a world beyond cirrhosis?
  2. HVPG measurement: How and when?
  3. Non-invasive evaluation of portal hypertension: Does it help?
  4. Update on the pharmacological and endoscopic management of portal hypertension
  5. Novel endovascular techniques: Always the last step?
  6. Precision medicine in portal hypertension: Are we there yet?

Portal hypertension school: State-of-the-art lecture by Dr Ian Rowe
Making sense of statistics in clinical trials: Lights and shadows of clinical studies generating evidence-based medicine

CME accreditation

EASL School of Hepatology – Progress, pitfalls and challenges in the management of portal hypertension, Barcelona, Spain, 19-11-2021-20-11-2021, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for a maximum of 11 European CME credits (ECMEC®s).

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at

Live educational activities, occurring outside of Canada, recognised by the UEMS-ACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada


The field of portal hypertension (PHT) faces many current challenges, regarding the variations in the etiology of cirrhosis. It also changes in the natural history of advanced chronic liver disease, once the etiological factors have been checked (i.e. patients’ sustained virological response after receiving antiviral treatment for HCV). This group of patients remain at high risk of developing PHT complications, but should we manage them differentially? Additionally, an improvement in diagnostic tools and awareness in the medical community have led to an increase in the identification of other etiologies of portal hypertension, other than cirrhosis, requiring specific approaches.

With the proposed programme and activities, the Barcelona Clinical School on portal hypertension will provide the following outcomes, adjusted to different needs:

  • PHT is not solely due to liver cirrhosis: The course will provide real clinical cases, in which the first clinical manifestation was a PHT-related complication in both the cirrhosis and non-cirrhosis etiology. We will work on finding similarities and differences regarding physical examination, symptoms, and characteristic findings in laboratory, imaging, and pathology exams. Participants will be encouraged to propose and discuss diagnostic and therapeutic algorithms during clinical case activities.
  • Etiological treatments change the natural history of advanced chronic liver disease. Participants will be encouraged to discuss and review the current evidence on how to manage these patients, via case discussions, e.g. How should one manage patients with clinical significant PHT in whom, after etiological treatment, the PHT becomes mild?
  • The importance of an accurate diagnosis of the underlying disease. We will emphasise the differences in prognosis, depending on underlying etiology and how patients should be treated according to evidence-based medicine. We will also underscore the lack of knowledge regarding specific aspects of management, what to do in such cases according to international consensus, and the research needed in this area.
  • The role of traditional diagnostic methods in the current era. We will focus certain clinical cases on how HVPG measurement can help with the diagnosis and treatment of PHT-related complications, due to different etiologies. Students  will see how measurements are taken (using real cases at the onsite facilities) and how tracings should be read. We will underline the minimum-quality criteria required for a portal pressure measurement to be trusted and provide real cases of HVPG and PPG measurement after TIPS placement, to illustrate how a non-accurate result may impair the management of patients.
  • Better knowledge of the new therapeutic armamentarium available including drugs, endovascular, and non-invasive techniques. We will revise recent trials focused on the management of PHT, not only pharmacological and endoscopic strategies, but also innovative endovascular techniques such as TIPS, interventional thrombosis recanalisation, and BRTO.
  • Evidence-based and individualised treatment of PHT. We will provide evidence and clinical examples focused on how stratifying patients according to their risk of treatment failure and bad outcomes can improve their survival.
  • Knowing how to interpret and criticise the methodology used in clinical studies is essential for understanding evidence-based medicine. We will stimulate attendees to review published studies critically and to separate the wheat from straw in published RCT, metanalysis, or systematic reviews. Having a better understanding of clinical statistics will improve the quality of the next generation of physicians. We will reinforce this concept with the attendees by analysing specific RCT/metanalysis/systematic reviews that try to answer specific questions raised by the patients presented in the clinical case discussions. This will be complemented with the state-of-the art session given by Dr Rowe, an excellent and thorough analyst of potential bias and over-interpretations of results obtained in clinical studies.

Show more Show less

About EASL Schools

The schools contribute to the training of new generations of hepatologists and are a major element of our association. Aimed at young fellows enrolled in hepatology-oriented departments or more experienced clinicians who want to be exposed to the newest trends in hepatology.

For selected applicants, EASL will cover transportation costs to attend the school and accommodation during the event (details will be provided individually once the selection process has been done).

Application is open to young fellows under the age of 35 (born after 17 September 1987) and/or still in training.

Approximately 30 places are available for each school and only EASL members are allowed to apply. Become an EASL member

Questions about EASL Schools?

Education is a priority for EASL and the association provides educational opportunities at every level. Traditionally, EASL Schools have been held in person, face to face. As the COVID-19 pandemic evolves, EASL may adapt to holding Schools online.

Due to strong interest in the EASL Schools, we have decided to give everyone additional time to complete and submit their applications. The new deadline is 23 February 2021. Please make sure your EASL membership is active before you submit your application.

Please make sure your EASL membership is active before submitting your application. Become an EASL member.

Please address your questions to and consult the Travel and attendance guidelines for EASL events

EASL Schools

See the entire offer and find out more on EASL Schools.

An application has been made for CME accreditation of this event.

Key Deadlines

  • 23 Nov, 2020 - 23 Feb, 2021

    Application period

Back To Top